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IMPORTANCE Evidence from preclinical models indicates that xenon gas can prevent the
development of cerebral damage after acute global hypoxic-ischemic brain injury but, thus
far, these putative neuroprotective properties have not been reported in human studies.
OBJECTIVE To determine the effect of inhaled xenon on ischemic white matter damage
assessed with magnetic resonance imaging (MRI).
DESIGN, SETTING, AND PARTICIPANTS A randomized single-blind phase 2 clinical drug trial
conducted between August 2009 andMarch 2015 at 2 multipurpose intensive care units in
Finland. One hundred ten comatose patients (aged 24-76 years) who had experienced
out-of-hospital cardiac arrest were randomized.
INTERVENTIONS Patients were randomly assigned to receive either inhaled xenon combined
with hypothermia (33°C) for 24 hours (n = 55 in the xenon group) or hypothermia treatment
alone (n = 55 in the control group).
MAIN OUTCOMES ANDMEASURES The primary end point was cerebral whitematter damage
as evaluated by fractional anisotropy from diffusion tensor MRI scheduled to be performed
between 36 and 52 hours after cardiac arrest. Secondary end points included neurological
outcome assessed using themodified Rankin Scale (score 0 [no symptoms] through 6
[death]) andmortality at 6months.
RESULTS Among the 110 randomized patients (mean age, 61.5 years; 80men [72.7%]), all
completed the study. There were MRI data from 97 patients (88.2%) amedian of 53 hours
(interquartile range [IQR], 47-64 hours) after cardiac arrest. Themean global fractional
anisotropy values were 0.433 (SD, 0.028) in the xenon group and 0.419 (SD, 0.033) in the
control group. The age-, sex-, and site-adjustedmean global fractional anisotropy value was
3.8% higher (95% CI, 1.1%-6.4%) in the xenon group (adjustedmean difference, 0.016 [95%
CI, 0.005-0.027], P = .006). At 6months, 75 patients (68.2%) were alive. Secondary end
points at 6months did not reveal statistically significant differences between the groups. In
ordinal analysis of themodified Rankin Scale, the median (IQR) value was 1 (1-6) in the xenon
group and 1 (0-6) in the control group (median difference, 0 [95% CI, 0-0]; P = .68). The
6-monthmortality rate was 27.3% (15/55) in the xenon group and 34.5% (19/55) in the
control group (adjusted hazard ratio, 0.49 [95% CI, 0.23-1.01]; P = .053).
CONCLUSIONS AND RELEVANCE Among comatose survivors of out-of-hospital cardiac arrest,
inhaled xenon combined with hypothermia compared with hypothermia alone resulted in
less white matter damage as measured by fractional anisotropy of diffusion tensor MRI.
However, there was no statistically significant difference in neurological outcomes or
mortality at 6months. These preliminary findings require further evaluation in an adequately
powered clinical trial designed to assess clinical outcomes associated with inhaled xenon
among survivors of out-of-hospital cardiac arrest.
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S urvivors of out-of-hospital cardiac arrest have a poorprognosiswith high rates of death and the likelihoodofhaving severe neurological problems.1-5 International
guidelines recommend theprovisionof therapeutichypother-
mia for comatose survivors of out-of-hospital cardiac arrest;
theseguidelinesarebasedon2studies2,3 inwhichpatientswith
an initial shockable rhythm who had been cooled to 33°C
achieved a better clinical outcome. However, a recent study4
suggested thatpreventinghyperthermia throughtargeted tem-
peraturemanagement to 36°C could be as neuroprotective as
33°C regardless of the initial rhythm at the time of the out-of-
hospital cardiac arrest. The optimal temperature for targeted
temperature management has yet to be defined and the effi-
cacy of the treatment is modest at best.2,3
Inanimal studies, theneuroprotectivepropertiesof the in-
halednoble gasxenonhavebeenestablished; these effects are
mediated through multiple putative molecular targets in the
pathways involved in postresuscitation brain injury.6-12 Neu-
roprotection associated with xenon has been especially evi-
dentwhencombinedwithhypothermia (33°Cto35°C)andboth
additiveandsynergistic interactionshavebeenreportedonthe
basis of histopathological and functional outcomes.9-12 A re-
cent study13 demonstrated that xenon inhalation is well tol-
erated and has favorable cardiovascular properties when ad-
ministered to patients treated with therapeutic hypothermia
after out-of-hospital cardiac arrest.
In this study, we investigated the effect of xenon on the
extent of cerebral white matter brain damage as assessed by
diffusion tensor magnetic resonance imaging (MRI) in coma-
tose survivors from out-of-hospital cardiac arrest who have
hypoxic-ischemic brain injury.
Methods
Study Design
Weconducteda randomized2-groupsingle-blindphase2clini-
cal drug trial at 2multipurpose intensive careunits inFinland.
The study was approved by the ethics committee of the
Hospital District of Southwest Finland and the institutional
review boards of the Helsinki University Hospital and the
Finnish Medicines Agency. An independent data and safety
monitoring committee reviewed data after enrollment of ev-
ery 4 patients and after each 6-month interval.
Thestudywasconductedaccordingtogoodclinicalpractice
andthecurrent revisionof theDeclarationofHelsinki14 guiding
clinical drug research inhuman subjects.Written informedas-
sentwas obtained from the next of kin or from the legal repre-
sentativeof thepatientwithin4hoursafterhospital arrival.The
patient’s familywas informedabout the right towithdrawfrom
the study at anypoint but that thedata collecteduntil possible
withdrawalcouldbeusedintheanalysesaspredefinedinthetrial
protocol (Supplement 1). Patientswere informedaccordingly if
they regainedconsciousness.Themodeofdeathwasclassified
asneurological,cardiological,ormultiorganasdescribedearlier.1
The patients were allocated in 1:1 ratio with random block
sizes of 4, 6, and 8 to receive either therapeutic hypothermia
treatment alone for 24 hours (defined as the control group) or
inhaled xenon (LENOXe, Air Liquide Medical GmbH) in com-
binationwith hypothermia for 24 hours (defined as the xenon
group). The treatment assignments were randomly generated
by a computer. Sequentially numbered sealed envelopeswere
used separately in the 2 centers for randomization, whichwas
performed after the assent was granted. Clinical investigators
performed the patient enrollment, randomization, and inter-
ventionassignment.Personnel involved in the treatmentof the
patient couldnotbeblindeddue topractical andsafety consid-
erations; however, theMRI analysis ofwhitematter injurywas
operator-independent, and the neurological end point evalu-
ators as well as the patients were blinded to the treatment.
The diffusion tensorMRI resultswere notmade available
to the clinicians treating the patients to avoid bias. For pa-
tients inwhomtherewaspremature terminationof thehypo-
thermia treatment, xenon administration alsowas discontin-
ued.A local neurological prognostication consensuswasused
indecisions towithdraw life-sustaining treatment (eMethods
in Supplement 2).
Patients
Comatose survivors of out-of-hospital cardiac arrest consecu-
tively admitted to the Turku and Helsinki University hospi-
tals were screened for eligibility. The main criteria for inclu-
sion were witnessed cardiac arrest from an initial rhythm
amenable to defibrillation (ie, ventricular fibrillation or non-
perfusing ventricular tachycardia and return of spontaneous
circulation within ≤45 minutes). Details of inclusion and
exclusion criteria appear in eTable 1 in Supplement 2.
Treatment Protocol
The patients underwent coronary angiographic interventions
whenclinically indicated. Integratedcareaftercardiacarrestand
patient monitoring adhered to recent recommendations.2,15
Therewasadherence to thedetailed treatmentprotocol regard-
ing cooling treatment and xenon intervention (eMethods in
Supplement 2). Inhaledxenonwas initiated immediately after
randomizationthroughaclosed-systemventilator (PhysioFlex,
Dräger).Oxygenandairweredelivered to achieve anend-tidal
xenon concentration of at least 40% (measured continuously
by the thermoconductivemonitor on the ventilator).
Outcome
Theprimaryendpointwas the severityof ischemicwhitemat-
ter brain injury as evaluatedby fractional anisotropy fromdif-
fusion tensorMRI.Although the studywasnotpowered tode-
tect statistical differences in clinical efficacy, the following
variableswere collected as exploratory secondary endpoints:
neurological outcome using the Cerebral Performance Cat-
egory (CPC) score (from1 [conscious, alert, able towork,might
have mild cognitive deficit] to 5 [death]) and the modified
RankinScale (mRS) score (from0[no symptoms] to6 [death]),
mortality at 6months, and the complication (eg, severebleed-
ing, pneumonia, sepsis, acute kidney injury,16 pulmonary
edema, ventricular arrhythmias, and epileptic status17) rate
within 7 days after cardiac arrest.
TheMini-Mental State Examination (MMSE) (score range,
0-30;≥24 indicatesno impairment) and theNational Institutes
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ofHealthStrokeScale (NIHSS) (score range,0-42;higher scores
indicate greater severity)wereused to assess the6-month ex-
ploratory neurocognitive outcome. The minimally clinically
important differences for CPC and NIHSS have not been es-
tablished; changes inMMSEof 4 ormore points have been in-
terpreted as clinically significant.18 Differences in mRS score
as low as 0.46 have been considered clinicallymeaningful by
practice guidelines.19,20
Diffusion TensorMRI
Thedifference intheseverityofwhitematterdamageinthecon-
trol andxenongroupswasanalyzedbycomparing thevaluesof
global fractional anisotropyanddiffusivity assessment (mean,
axial, andradial)obtainedfromthediffusiontensorMRI.White
matterdamageevokesalossofmicrostructuralorganizationthat
canbequantifiedby the lossofdirectionality in thediffusionof
watermolecules inthewhitemattertracts.Fractionalanisotropy
is a scalar value representing this directionality of water diffu-
sion; lower fractionalanisotropyvaluesare indicativeof lessor-
ganized diffusion and indicate more extensive white matter
damage.21Meandiffusivityvaluesmeasureoveralldiffusionand
mostly representcellularityandmembranedensity; theyareaf-
fectedbyseveral pathological processes (eg, edemaandnecro-
sis). Axial diffusivity values represent the amount ofwater dif-
fusingalongtheprincipalaxisof thediffusionellipsoid,whereas
radial diffusivity values depict diffusion perpendicular to the
principalaxis; thesevaluesreflectaxonal injuryandmyelin loss,
respectively.22-24
MRI Protocol and Image Processing
Patientswere scheduled toundergobrainMRIwithin 16hours
after rewarming; ranging from 36 to 52 hours after out-of-
hospital cardiac arrest. Magnetic resonance imagingwas per-
formed with a Verio 3T scanner (Siemens Medical Solutions)
atbothcenters,with identical imagingprotocols.Diffusion ten-
sorMRI data was preprocessed using DTIprep quality control
software (eMethods in Supplement 2). Version 5.0 of the FSL
software package (FMRIB) was used for the tract-based spa-
tial statistical analysis.25-29 This observer-independent and
hypothesis-freemethodhas theability tospatially locategroup
differences in the diffusion tensor MRI data.
Fractional anisotropy and diffusivity maps were calcu-
lated for each patient and these images were projected on a
meanskeletonwithavoxel sizeof 1 × 1 × 1mm(ie, 119013vox-
elsperpatient),which represents thecentersof allmajorwhite
matter structures. These skeletonized imageswere thenused
for voxel-wise statistics to identify all tracts with voxels re-
vealing statistically significant differences in diffusion para-
meters. Localization and labeling of the major white matter
tractswere confirmedaccording to the JohnsHopkinsUniver-
sitywhitematter tractographyatlas.30Additionaldetails of the
MRIprotocol,qualitycontrolof imaging, imageprocessing,and
tract-based spatial statistics appear in the eMethods, eTable
2, and eTable3 in Supplement 2.
Statistical Analyses
The sample size was based on a power analysis of fractional
anisotropyvalues.However, a clinically relevant difference in
the effect size had not been established. Therefore, this dif-
ference was arbitrarily set at 15%, which proved to be unreal-
istically large given that the difference in themean fractional
anisotropy values between those patients who survived and
thosewhodiedwasonly6.4% (eTable 7 in Supplement 2). The
numberofpatientswaspredeterminedbasedon the result ob-
tained from the power analysis. Accordingly, it was esti-
mated that 55 patients per group would be needed to reveal
an absolutemediandifference of 15% in fractional anisotropy
between the groups (85% power and a 2-sided α level of .05).
The Shapiro-WilkW test was used to test for normality of
all continuous variables. The 2-sample t test and the Mann-
Whitney test were used to compare continuous variables be-
tweenthegroups.Categoricalvariableswereanalyzedwith the
χ2 test or theFisher exact test. TheMann-Whitney test and the
Hodges-Lehmann estimate were used for the ordinal vari-
ables of mRS and CPC to calculate median differences be-
tween the groups. Between-group differences in global frac-
tionalanisotropyanddiffusivityvalues (radial, axial, andmean)
were analyzed using the 2-sample t test and analysis of cova-
riancewithadjustment forage, sex,andsiteas recommended.31
Permutation-based voxel-wise statistical analysis of frac-
tional anisotropy valueswas performedwith tract-based spa-
tial statistics in conjunction with family-wise error correc-
tion for multiple comparisons across space.29
The follow-up time for survival analysis was calculated
fromthe timeof cardiac arrest until deathor6months.A com-
plete case analysis was applied to the primary end point due
to missing MRI data for 6 patients in the control group and 7
patients in thexenongroup.Multiple imputationwasnot per-
formeddue to lackof a goodprognosticmodel topredict valid
imputedvalues formissingdata.Kaplan-Meier survival curves
and a Cox proportional hazards model were used to compare
mortality at 6 months between the groups in the intention-
to-treat population. The proportional hazards assumptions
were evaluated with the log-cumulative hazard plot and
martingale-based residuals; the assumptions were met. The
observation was censored in the survival analysis if the pa-
tientwaswithdrawn fromthe studyorwas still alive at theend
of the6-month follow-up.Analyseswereadjustedwith the fol-
lowing prognostic factors: age, sex, time to return of sponta-
neouscirculation,coolingrate,andsite.32 Inaddition, theglobal
fractional anisotropy and diffusivity values were used as fac-
tors associated with 6-month mortality after adjustment for
age, sex, group, and site.
A 2-sided P value of less than .05was considered statisti-
cally significant. Secondary end points were not adjusted for
multiplicity and were therefore described as exploratory.
Statistical analyses were performed using SAS version 9.4
(SAS Institute Inc).
Results
Patients
TurkuUniversityHospital recruited patients betweenAugust
2009 and September 2014; for Helsinki University Hospital,
the corresponding dates were between October 2012 and
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September 2014; and the 6-month follow-up was completed
during March 2015. A total of 224 patients were screened for
eligibility and of these, 110 (aged 24 to 76 years) were en-
rolled with 55 randomly assigned to the xenon group and 55
to the control group (Figure 1). The patient characteristics of
the 2 randomized groups were similar (Table 1). One patient
in the xenon group was withdrawn from the study 6 days af-
ter the index event by the next of kin.
Treatment
Themeanend-tidalxenonconcentrationwas48.2%(SD,3.8%)
and the rangewas 41.4% to 56.9%.Neither core temperatures
on admission to the intensive care unit nor during treatment
and intervention differed between the groups; time fromcar-
diac arrest to hypothermia targetwas also similar (Table 1 and
eTable 4 in Supplement 2). There were no differences in the
routinely measured laboratory parameters (eTable 4). Deci-
sions to withdraw life-sustaining treatment were based on a
consensus agreement that there was a poor neurological
outcome (eTable 5). Of the 34 patients who died, 29 (85.3%)
had a neurological mode of death (eTable 6).
Primary End Point
Diffusion tensorMRI data for the tract-based spatial statistics
analysis were obtained from 48 patients in the xenon group
and 49 patients in the control group a median of 53 hours
(interquartile range [IQR], 47-64hours) after cardiac arrest. At
6 months, 75 patients (68.2%) were alive and able to provide
data for follow-up. The reasons for missing MRI data appear
in Figure 1. Using tract-based spatial statistics analysis, a
Figure 1. Flow of Participants in the Study of Effect of Inhaled Xenon on CerebralWhiteMatter Damage in
Comatose PatientsWho Experienced Out-of-Hospital Cardiac Arrest
224 Patients assessed for eligibility
114 Excluded
66 Study personnel not available
5 Had high inspiratory oxygen fraction
2 Primary cardiac rhythm unclear
1 Delay from return of spontaneous
circulation to hospital too long a
1 In another drug trial
1 Emergency medical service delay unclear
1 Asphyxia due to vasculitis
25 Next of kin could not be reached
11 Did not meet inclusion criteria
5 Xenon delivery device already in use
4 Had permanent pacemaker
1 Had emergency coronary surgery
1 Prosthesis with no MRI compatibility
1 Previous enrollment in same trial
110 Randomized
48 Included in the complete case analysis of the
primary end point
7 Excluded from the analysis of primary end point
(missing MRI data)
2 Deaths (of which 1 was primary cerebral event)
2 MRI technical failure
1 Safety reason (poor condition)
2 Had noncompatible MRI material (pacemaker)
55 Included in the intention-to-treat analysis of the
secondary end points (mortality at 6 mo and
complication rates)
49 Included in the complete case analysis of the
primary end point
6 Excluded from the analysis of primary end point
(missing MRI data)
3 Deaths
2 MRI technical failure
1 Safety reason (poor condition)
55 Included in the intention-to-treat analysis of the
secondary end points (mortality at 6 mo and
complication rates)
0 Lost to follow-up
1 Patient was withdrawn 6 d after randomization
because of family member request
1 Discontinued treatment early (primary cerebral event)
0 Lost to follow-up
0 Discontinued treatment early
55 Randomized to receive the combination of xenon
and hypothermia treatment
53 Received treatment as randomized
1 Mistakenly randomized with pulseless electric
activity as the primary rhythm
1 Mistakenly randomized with primary
cerebral event
2 Did not receive treatment as randomized
1 Technical failure of xenon delivery device
1 Safety reason (subarachnoid hemorrhage)
55 Randomized to receive hypothermia
treatment alone
54 Received treatment as randomized
1 Did not receive treatment as randomized
(died prior to intensive care admission)
MRI indicates magnetic resonance
imaging.
a Patient was first transmitted to the
wrong hospital; an initiation of
possible xenon treatment was not
possible within 4 hours.
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statistical parametric map containing 119013 voxels was cre-
ated to visualize the spatial distribution of areas with signifi-
cantly lower fractional anisotropy in the control group
(Figure 2). The fractional anisotropy was significantly lower
in 41.7% of the voxels in the control group than in the xenon
group (ie, 58.3% of the voxels did not differ between the
groups). The tract-wise distribution of the percentages ap-
pears in Figure 2. None of the voxels revealed significantly
lower fractional anisotropy values in the xenon group.
Themeanglobal fractional anisotropy values of all voxels
presented inFigure2were0.433 (SD,0.028) in thexenongroup
and 0.419 (SD, 0.033) in the control group (P = .03; Table 2).
Theage-, sex-, andsite-adjustedmeanglobal fractional anisot-
ropy value was 3.8% higher (95% CI, 1.1% to 6.4%) in the
xenongroup (adjustedmeandifference, 0.016 [95%CI, 0.005
to 0.027], P = .006). The mean radial diffusivity value was
0.598 (SD, 0.051) for the xenon group and 0.619 (SD, 0.062)
for the control group.Theadjusted radial diffusivityvaluewas
3.9% lower (95%CI,0.5%-7.4%) in thexenongroup than in the
control group (adjusted mean difference, −0.024 [95% CI,
−0.046 to−0.003],P = .03; Table 2). Collectively, these quan-
titativedifferences indiffusiontensorMRIvalues indicatedthat
there had beenmore severe disruption of whitematter in the
control group.
Of the diffusion tensor MRI measures, global fractional
anisotropyexhibited thebest independentpredictivevalue for
mortality during the 6-month follow-up period (mean [SD] of
0.433 [0.026] in thesurvivingpatientsvs0.407[0.035] in those
who died per 0.01-unit increase in fractional anisotropy); the
age-, sex-, group-, andsite-adjustedhazard ratiowas0.81 (95%
CI, 0.69-0.94;P = .006) (eTable 7 in Supplement 2). Themean
global fractional anisotropy was 6.4% higher (95% CI, 3.3%-
9.5%) in the surviving patients than in those who died.
Secondary End Points
In the intention-to-treat population, the Kaplan-Meier sur-
vival estimateafter6-month follow-upwas27.3%(15/55) in the
xenon group and 34.5% (19/55) in the control group (adjusted
hazard ratio, 0.49 [95% CI, 0.23-1.01], P = .053; eFigure 1 in
Supplement 2).
At 6months, neurological outcomewas not significantly
different between the groups as assessed with the CPC
(median score of 1 [IQR, 1-5] for the xenon group and 1 [IQR,
1-5] for the control group;mediandifference, 0 [95%CI, 0-0],
P = .93) or the mRS (median score of 1 [IQR, 0-6] for the xe-
non group and 1 [IQR, 0-6] for the control group; median dif-
ference, 0 [95% CI, 0-0], P = .68).
Similarly, the rates of serious adverse eventswerenot sig-
nificantly different between the groups at 6 months (Table 3
and eTable 8 in Supplement 2). In addition, therewas not any
difference in neurocognitive outcome measures of MMSE
(median of 29 [IQR, 27-30] for the xenon group and median
of 29 [IQR, 28-30] for the control group) and NIHSS (median
of 0 [IQR, 0-0] for the xenon and control groups).
Table 1. Baseline Characteristics in the Intention-to-Treat Populationa
Xenon Group
(n = 55)
Control Group
(n = 55)
Age, median (IQR), y 63 (55-70) 60 (54-67)
Male sex 41 (74.5) 39 (70.9)
Coronary artery disease 38 (69.1) 40 (72.7)
Hypertension 22 (40.0) 26 (47.3)
Congestive heart failureb 6 (10.9) 4 (7.3)
Diabetes 9 (16.4) 8 (14.5)
Asthma or chronic obstructive pulmonary disease 6 (10.9) 9 (16.4)
Dyslipidemia 15 (27.3) 23 (41.8)
Smoker 17 (30.9) 22 (40.0)
ST-elevation myocardial infarction 15 (27.3) 19 (34.5)
Previous stroke 10 (18.2) 12 (21.8)
White matter degeneration score
No. of patients 48 49
Fazekas score 0-1c 39 (81.3) 38 (77.6)
Fazekas score 2-3c 9 (18.8) 11 (22.4)
Resuscitation details
Bystander resuscitation 38 (69.1) 40 (72.7)
Delay in emergency medical service, mean (SD), min 8.4 (3.4) 8.7 (3.2)
Return of spontaneous circulation, mean (SD), min 22.6 (8.3) 21.9 (7.0)
No flow, median (IQR), mind 0 (0-6) 0 (0-1)
Core temperature before start of cooling, median (IQR), °C 34.9 (34.4-35.8) 35.4 (34.0-36.3)
Time from out-of-hospital cardiac arrest to target temperature,
median (IQR), min
290 (263-338) 336 (254-395)
Cooling rate, median (IQR), °C/h 0.43 (0.30-0.50) 0.43 (0.20-0.50)
Time from out-of-hospital cardiac arrest to initiation of xenon,
median (IQR), min
247 (209-278)
Abbreviation: IQR, interquartile
range.
a Data are expressed as No. (%)
unless otherwise indicated.
bBased on patient history and
angiographic findings.
c Amagnetic resonance imaging
system of scoring for white matter
hyperintensities that are often
observed in older persons
(65 years) and are considered
small vessel disease. A score of 0
indicates no lesions; 1, punctate foci;
2, beginning confluence of foci;
and 3, large confluent areas.
d Indicates period from cardiac arrest
to start of any chest compression by
bystander or emergencymedical
personnel.
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Discussion
Theprincipalfindingwasthatinhaledxenonincombinationwith
therapeutichypothermiatreatmentpreservedwhitemattertracts
better thanhypothermia treatmentalone insurvivorsofcardiac
arrest.Thiswas reflectedbyhigher fractional anisotropyvalues
indicativeofanattenuationofongoingdisruptionofwhitemat-
termicrointegrity, and the lower radial diffusivity, a reflection
of less demyelination of thewhitematter tracts.
Diffusion tensorMRI and tract-based spatial statistics rep-
resentanautomatedquantitativeassessmentof injury towhite
matter tracts.25 The fractional anisotropy, acquired fromdiffu-
siontensorMRI, isacorrelateof themicrointegrityofwhitemat-
ter tracts.21 Lower fractional anisotropyvaluesobtainedwithin
3weeksofcardiacarresthavebeenassociatedwithapoor1-year
Table 2. Results of Diffusion TensorMagnetic Resonance Imaging in the Complete Case Population
Global Values
Unadjusted Mean (SD) Mean Difference (95% CI) P Value
Xenon Group
(n = 48)
Control Group
(n = 49) Unadjusted Adjusteda Unadjusted Adjusteda
Fractional anisotropy 0.433 (0.028) 0.419 (0.033) 0.014 (0.002 to 0.026) 0.016 (0.005 to 0.027) .03 .006
Type of diffusivity, 10−3 mm2/s
Axial 1.190 (0.052) 1.199 (0.051) −0.009 (−0.030 to 0.012) −0.011 (−0.031 to 0.010) .40 .30
Radial 0.598 (0.051) 0.619 (0.062) −0.021 (−0.043 to 0.002) −0.024 (−0.046 to −0.003) .08 .03
Mean 0.795 (0.050) 0.812 (0.056) −0.017 (−0.038 to 0.005) −0.020 (−0.040 to 0.0007) .13 .06
a Data are adjusted for age, sex, and site.
Figure 2.Whole Brain Visualization of the Results of CerebralWhiteMatter Damage
P <.05
P ≥.05
R L
White matter damage leads to a loss of microstructural organization that can be
quantified by the loss of directionality in the diffusion of water molecules in the
white matter tracts. Fractional anisotropy is a scalar value representing this
directionality of water diffusion; lower fractional anisotropy values are
indicative of less organized diffusion and are an index of more extensive white
matter damage. The visualization presents the results of the voxel-wise
tract-based spatial statistics analysis of fractional anisotropy values between
the xenon group and the control group. Voxels with significantly (P < .05,
family-wise error corrected for multiple comparisons) lower fractional
anisotropy values in the control group were identified and are shown in red in
the statistical visualization (ie, 41.7% of all 119 013 analyzed voxels), whereas the
areas in which there was no significant difference in fractional anisotropy values
between the groups are shown in green (ie, 58.3% of all analyzed voxels).
According to the Johns Hopkins University white matter tractography atlas, the
tract-wise distribution of the voxels (percentages in parentheses below) with
significantly (P < .05; family-wise error corrected for multiple comparisons)
lower fractional anisotropy in the control group (marked red in the figure) were
as follows: cingulum (cingulate gyrus) (54.6%), cingulum (hippocampal region)
(1.4%), forceps minor (49.4%) andmajor (35.5%), superior longitudinal
fasciculus (49.3%), inferior longitudinal fasciculus (34.8%), anterior thalamic
radiation (45.1%), inferior fronto-occipital fasciculus (41.0%), corticospinal tract
(28.7%), uncinate fasciculus (36.4%), and the body of corpus callosum (72.3%).
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neurological outcome.33Weanalyzed thediscriminatingvalue
of the global fractional anisotropy for survival to estimate
whetheraclinicalbenefitcouldaccruefromthehigherfractional
anisotropyvalues in thexenongroup.We found that themean
globalfractionalanisotropyvaluewassignificantlyhigheramong
survivorsandinthexenongroupcomparedwiththosewhodied
and those in the control group. In addition, of all the diffusion
tensorMRImeasures, lowerfractionalanisotropywasassociated
withmortality during the 6-month follow-up.
With regard to the other diffusion tensor MRI para-
meters, each of the diffusivity values was lower in the xenon
group; however, the reductions only achieved statistical sig-
nificance for radial diffusivity (Table 2). In an earlier study in
whichpatientswith severe brain injurywere scannedat times
varying from 5 days to 7 weeks after cardiac arrest, the radial
diffusivity values were significantly higher than the corre-
sponding values from healthy volunteers.34 The mean diffu-
sivitydata from14patients treatedwithhypothermiaandwho
received anMRI scan within 3 days of their cardiac arrest did
not predict outcome.35 In this study, higher unadjusted ra-
dial and mean diffusivity values were independent predic-
torsofmortalityduring the6-month follow-up.However,none
of theadjusteddiffusivityvaluescouldclearlydiscriminatebe-
tweensurvivors andnonsurvivors andhence theclinical value
of these metrics remains unproven.
Althoughthestatisticallysignificantdifference(P = .006)be-
tween patients treatedwith xenon and those untreated for ad-
justedmean global fractional anisotropy values was only 3.8%
(adjustedmean difference of 0.016), thismagnitude of change
needs tobe considered in the context of the statistically signifi-
cant difference between survivors and those who died of
6.4% (eTable 7 in Supplement 2). In addition, a diluting effect
of voxels, without significant difference between the groups
(displayed in green in Figure 2) in the final tract-based spatial
statistical analysis, resulted in reduced absolute mean differ-
ence in the global fractional anisotropy values (Table 2).
Thus, the treatment effect size of xenon on global fractional
anisotropy was more than 50% of the difference in this pri-
maryoutcomemeasureobservedbetweensurvivors and those
whodied.Furthermore, theseverityofobservedwidespread in-
jury was demonstrated by the finding that 41.7% of the white
matter tracts on average, including major commissural, asso-
ciative, and projection fibers, were significantlymore severely
injured in the control group than in the xenon group. These fi-
bersare involvedinmultiple importantcognitivefunctions,such
asattention,memory, language, emotions, auditory,visual and
executive processing, andmotor functions of the body.
The volume ofwhitematter constitutes 50%of total brain
volume in humans and is highly vulnerable to even brief
ischemia.36 The present results indicate that the higher radial
diffusivity (demyelination) was mainly responsible for the
lower fractional anisotropy in patients in the control group.24
An earlier study revealed thatN-methyl-D-aspartate receptors
are expressed inmyelin of whitematter oligodendrocytes and
become activated during ischemia37; xenon is a N-methyl-D-
aspartate receptorantagonist andacompetitive inhibitor at the
glycine coactivation site of that receptor.7,8Althoughnotdem-
onstratedhere, it is possible that sensitive tests of neurocogni-
tivefunctioninanappropriatelypoweredclinical trialmaytrans-
late the improvement inwhitematter intoclinicalbenefits.This
hypothesis warrants further investigation.
Although a benefit of xenon onwhitematter damagewas
observed, therewere no significant differences in the explor-
atoryanalysis ineitherneurological (CPCormRSscore;Table3)
or cognitive outcomes (NHISS or MMSE score) between the 2
treatmentgroups.Thestudywasunderpoweredtodetectasta-
tistically significant difference in clinical outcome due to the
rarity of severe neurological impairment in long-term survi-
vors after cardiac arrest; about 90% of patients who experi-
encecardiac arrest andarealiveat the6-month follow-uphave
Table 3. Neurological Outcome in the Complete Case Populationa
Description of Category
Xenon Group
(n = 54)b
Control Group
(n = 55)
Cerebral Performance Category score
1 Good cerebral performance: conscious, alert, able to work, might have
mild cognitive deficit
30 (55.6) 32 (58.2)
2 Moderate cerebral disability: conscious, sufficient cerebral function for
independent daily life
7 (13.0) 4 (7.3)
3 Severe cerebral disability: conscious, dependent on others for daily
support; ranges from ambulatory state to severe dementia
2 (3.7)c 0
4 Coma or vegetative state 0 0
5 Death 15 (27.8) 19 (34.5)
Modified Rankin scale score
0 No symptoms 23 (42.6) 22 (40.0)
1 No significant disability: able to carry out all usual activities, despite
some symptoms
7 (13.0) 8 (14.5)
2 Slight disability: able to look after own affairs without assistance,
but unable to carry out all previous activities
6 (11.1) 5 (9.1)
3 Moderate disability: requires some help, but able to walk unassisted 1 (1.9) 1 (1.8)
4 Moderately severe disability: unable to attend to own bodily needs
without assistance
2 (3.7)c 0
5 Severe disability: requires constant nursing care and attention 0 0
6 Death 15 (27.8) 19 (34.5)
a Data are expressed as No. (%).
There was no significant difference
between groups in Cerebral
Performance Category score
(P = .93) or modified Rankin Scale
score (P = .68).
bOne patient was withdrawn
from the study 6 days after
the index event.
c Prior the index event, 1 patient had a
Cerebral Performance Category
score of 3 (due tomental
retardation) and amodified Rankin
Scale score of 4.
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experienced a good neurological outcome (CPC score of 1
or 2).38-41 In both groups, the MMSE score was 29 of a maxi-
mum score of 30; this was very similar to the score of 28 that
was reported in a large targeted temperature management
study comparing comatose cardiac arrest survivors treated at
33°C and 36°C, and may reflect the small effect size that this
test is capable of eliciting.40 Therefore, in subsequent stud-
ies,more sensitivemethodswill beneeded for assessing func-
tional neurocognitive disorders.
Thestudyhadseveral limitations.First, the secondaryend
points were not adjusted for multiplicity and therefore were
described as exploratory. Second, in the analysis of secondary
end points, we did not have sensitive enough neurocognitive
tests to measure subtle degrees of functional disability in the
smallnumberofpatients that couldbeassessed.Third,ourpri-
mary end point was based on a single time point in the early
stage of evolving brain injury; it remains to be determined
whether the improvement in thediffusion tensorMRImetrics
persists and can contribute to a long-term clinical benefit.
Fourth, all patients received delayed xenon intervention and
therefore it is possible that the observed effect on white mat-
termayhavebeendifferent if thexenon interventionhadbeen
initiated earlier after the ischemic event. Fifth, althoughmore
than 80%of the deaths in this studywere due to severe ische-
micbrain injury,underlyingcardiacdiseasealsomayhavecon-
tributed to poor outcomes, therefore, it is unknown whether
some patients might have benefitted from the improved car-
diovascular stabilityassociatedwithxenon.13 Sixth, thesample
size calculation of the present study was based on an unreal-
istic assumptionof theabsolutedifferenceof fractional anisot-
ropyvaluesbetweenthegroups.Nonetheless,because thevari-
ance of the variable was proportionally smaller, there was a
statistically significant difference between the groups; how-
ever, theabsolutedifference in fractional anisotropywassmall.
Seventh, thepredictivevalueofglobal fractional anisotropy for
survival needs to be prospectively validated before designat-
ing the improvement inwhitematter injury seen in the xenon
group as a marker for improved survival.
Conclusions
Among comatose survivors of out-of-hospital cardiac arrest,
inhaledxenoncombinedwithhypothermiacomparedwithhy-
pothermia alone resulted in lesswhitematter damage asmea-
sured by fractional anisotropy of diffusion tensor MRI. How-
ever, there was no statistically significant difference in
neurological outcomes or mortality at 6 months. These pre-
liminary findings require further evaluation in an adequately
powered clinical trial designed to assess clinical outcomes
associated with inhaled xenon among survivors of out-of-
hospital cardiac arrest.
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